

# Treatment of Bipolar Disorder in Cerebral Palsy: Challenges in Antipsychotic Use

*by* Jana Publication & Research

---

**Submission date:** 17-Jun-2025 11:52AM (UTC+0700)

**Submission ID:** 2690321095

**File name:** IJAR-52283.docx (31.58K)

**Word count:** 3254

**Character count:** 19604

# Treatment of Bipolar Disorder in Cerebral Palsy: Challenges in Antipsychotic Use

## Abstract

10

Cerebral palsy (CP) is a neurodevelopmental disorder that frequently coexists with psychiatric conditions, including bipolar disorder. Treating bipolar disorder in this population poses significant clinical challenges due to the clinical heterogeneity and comorbidity associated with CP. Adverse effects of antipsychotics tend to have a more profound impact on the quality of life in individuals with CP compared to the general population. Therefore, they represent a more serious clinical concern.

This article aims to highlight the challenges of choosing antipsychotics for managing bipolar disorder in CP patients. To our knowledge, this topic has not been previously addressed in the literature. We propose that the antipsychotic selection should be guided by individual clinical characteristics, including CP subtype, mobility status, affected limbs, body mass index (BMI), and pre-existing orthopedic conditions. Personalized treatment may help providers better balance the risks of extrapyramidal symptoms and metabolic syndrome, thereby improving therapeutic outcomes and overall quality of life for this overlooked patient population.

**KEYWORDS:** CEREBRAL PALSY, ANTIPSYCHOTICS, EXTRAPYRAMIDAL SYMPTOMS, METABOLIC SYNDROME, WEIGHT GAIN

## Background

10

Cerebral palsy (CP) is a severe neurodevelopmental disorder that affects 3 out of every 1,000 live births. In this disorder, an injury to the motor segment of the brain leads to movement disorders in patients. These disorders are classified into three main types: spastic (muscle contractions), dyskinetic (involuntary, uncontrolled movements), and ataxic (poor coordination). Spastic CP is the most prevalent form, and it affects approximately 80% of patients. Based on which limbs are affected, it can be further categorized as hemiplegic (one side of the body), diplegic (both legs), or quadriplegic (all four limbs). Common clinical features of spastic CP include increased deep tendon reflexes, tremors, hypertonia, muscle weakness, a characteristic scissors gait, and toe walking.

The dyskinetic type, present in about 10–20% of patients, is associated with extrapyramidal symptoms such as athetosis and dystonia. Athetosis is slow, snakelike, writhing movements, particularly in the fingers, which exacerbate during periods of stress. Dystonia is an involuntary, sustained muscle contraction.

The rarest form is ataxia, which affects 5–10% of individuals with CP. It impairs balance and coordination; patients often exhibit wide-based gait and intention tremors. Some patients may also

present with mixed-type CP, displaying features from multiple categories.<sup>1,2</sup>

Depending on the severity of the disorder, various comorbidities may occur: intellectual disability, inability to walk or speak, epilepsy, hip displacement, and incontinence.<sup>3</sup>

22

Cerebral palsy (CP) is caused by disturbances in fetal brain development. The risk factors associated with CP include placental abruption, uterine rupture, intrauterine infections, prematurity, maternal fever during pregnancy, congenital anomalies, complications related to multiple gestations, and birth asphyxia.

Cortical neurogenesis occurs during early gestation, particularly up to 24 weeks. Disruptions in this developmental process due to genetic abnormalities, intrauterine infections, or exposure to toxic agents can lead to structural brain abnormalities.

In the later stages of pregnancy, myelination, axonal and dendritic growth, and synapse formation occur. At this stage, ischemia and hypoxia contribute to the development of CP.<sup>1</sup>

It is well recognized that having CP significantly reduces individuals' quality of life and leads to considerable psychological distress, resulting in anxiety and depression. Research has shown that the prevalence of psychiatric disorders in CP patients is remarkably higher than in the general population, except for substance use disorders. Having intellectual disability further increases the prevalence of severe psychiatric conditions, such as psychotic disorders and bipolar disorder. On the other hand, among individuals with CP, those without intellectual disability have appeared to have an elevated risk of developing anxiety and depressive disorders.<sup>4</sup>

According to one study, attention-deficit/hyperactivity disorder (ADHD) is the most common psychiatric comorbidity in this population.<sup>5</sup> Other frequently reported psychiatric disorders in

individuals with CP include obsessive-compulsive disorder, oppositional defiant disorder, schizophrenia, bipolar disorder, and generalized anxiety disorder.<sup>4,6</sup> These findings highlight the importance of regular mental health evaluations in individuals with CP. Unfortunately, communication difficulties commonly seen in this population may cause psychiatric symptoms to be overlooked, which can lead to delays in diagnosis and worsening of mental health conditions.

<sup>7</sup> Bipolar disorder is a mood disorder characterized by manic and depressive episodes. A manic episode is defined by an elevated or irritable mood, heightened energy, inflated self-esteem, decreased need for sleep, and racing thoughts lasting for at least a week. In contrast, a depressive episode is composed of feelings of worthlessness, anhedonia, and disturbances in appetite and sleep.<sup>12</sup> Approximately 1.2% of the general population is affected by bipolar disorders. However, it affects 2.1% of the CP patients and 2.7% of the CP patients who also have intellectual disability.<sup>4</sup> Treatment of bipolar disorder in patients with CP requires special attention due to possibly more severe extrapyramidal and metabolic adverse effects. In this article, we will explore the difficulties and limitations in the management of bipolar disorder in patients with Cerebral Palsy.

## Bipolar Disorder Management in Cerebral Palsy

Bipolar treatments available and approved by the FDA are mainly antidepressants for bipolar depression, as well as antipsychotics and mood stabilizers for mania, depression, and maintenance. Compared with mood stabilizing medications, second-generation antipsychotics have a faster onset of action, making them a first-line treatment for severe acute manic symptoms. Traditional mood stabilizers, such as lithium, valproate, and carbamazepine, are also effective in treating active mania. For long-term treatment, most of the second-generation antipsychotics (except lurasidone and paliperidone), lithium, valproate, and lamotrigine are approved.<sup>8</sup>

Patients with CP may be prone to neurologic adverse effects due to underlying brain conditions, as suggested in various studies. One study shows serotonin syndrome in CP patients with atypical drugs like SSRI monotherapy, lithium, and olanzapine. Serotonin syndrome is characterized by clonus, diaphoresis, hyperreflexia, hypertonia, and hyperthermia, and typically occurs with two or more serotonergic agents.<sup>9</sup> Another study indicated that administering haloperidol to a patient with cerebral palsy (CP) resulted in destructive motor and cognitive effects. The patient became unresponsive and showed no spontaneous movement. The study suggested that decreased levels of dopamine are observed in animal studies of cerebral hypoxia in the developing brain, and given that cerebral hypoxia is one of the main pathologies of CP, this could lead to significantly reduced baseline dopamine levels in individuals with CP. Consequently, this makes them more susceptible to the effects of pharmacological dopamine blockade.<sup>10</sup>

Also, approximately half of the patients with CP have an intellectual disability.<sup>3</sup> As having an organic brain disorder and intellectual disability is a risk factor for Neuroleptic Malignant Syndrome, when these individuals have an affective disorder, they are at an increased risk for it.<sup>11</sup> Therefore, when prescribing antipsychotics to these patients, it is essential to consider these risks.

Using antipsychotics for patients with cerebral palsy (CP) requires careful consideration. Due to the underlying movement disorder, the risk of experiencing extrapyramidal side effects increases. Extrapyramidal symptoms (EPS) include akathisia (motor restlessness), dystonia (sustained muscular contraction), parkinsonism (bradykinesia, rigidity, tremor), tardive dyskinesia (late-onset choreiform movements), and tardive dystonia (late-onset dystonia).<sup>12</sup>

CP affects motor control, and EPS can exacerbate movement difficulties, making daily activities even more challenging. The following examples illustrate how EPS may manifest in this population.

Dystonia may increase muscle tone and worsen the already present spasticity in these patients, leading to further stiffness. For patients with ataxic CP, impaired balance combined with EPS symptoms such as parkinsonism could significantly elevate the risk of falls and related injuries.<sup>13</sup> Tardive dyskinesias, including tardive dystonia, are persistent, late-onset adverse effects that may last up to years, and they occur with long-term use of antipsychotics.<sup>12</sup> Tardive dyskinesia mainly affects the orofacial muscles but can also involve the limbs. This limb involvement may contribute

to gait disturbances that already exist in CP patients.<sup>3,14</sup> Tardive dystonia can affect multiple body areas, including neck musculature, trunk, limbs, and oromandibular muscles.<sup>14</sup> Oromandibular dystonia (OMD) is an involuntary contraction of the jaw, tongue, and facial muscles. These issues can worsen speech disorders and swallowing difficulties that are already common in CP patients. Speech disorders in OMD can be summarized by sigmatism (difficulty pronouncing sibilant sounds) and poor phoneme linkage (difficulty connecting speech sounds), which causes reduced fluency. Dysphonia or difficulty in vocalization is also common in OMD. These adverse effects of EPS make social interactions more challenging, causing anxiety in patients.<sup>15</sup> Additionally, having EPS significantly lowers the quality of life<sup>16</sup> and is the direct cause of medication discontinuation for many patients. Along with the fact that psychiatric patients are poor historians, the communication problems with CP patients can cause EPS to go undiagnosed.<sup>17</sup> Furthermore, symptoms like akathisia, akinesia, and acute dystonia may resemble common psychiatric symptoms, complicating the diagnosis of EPS.<sup>17</sup>

EPS arise from the dopamine D2 receptor antagonist activity of drugs in the striatum. Research suggests a D2 receptor occupancy rate of 80% or higher is associated with a high likelihood of demonstrating EPS. An occupancy rate between 70% and 80% indicates a moderate probability of EPS, while an occupancy rate below 70% is generally not associated with EPS. Mainly, the goal is to maintain sufficient D2 antagonism to achieve an antipsychotic effect while minimizing injury to the D2 dopamine system to avoid EPS. Second-generation antipsychotics (SGAs) such as aripiprazole, olanzapine, risperidone, olanzapine, and quetiapine typically have a superior EPS profile compared to first-generation antipsychotics (FGAs). High-potency FGAs like haloperidol are more likely to cause EPS due to their highest occupancy rates. Among SGAs, research demonstrates that risperidone has a more unfavorable side effect profile than the other options. In contrast, quetiapine and clozapine have the lowest D2 occupancy rates, so they exhibit the lowest incidence of EPS compared to other SGAs.<sup>17</sup>

In order to reduce this occupancy, some medications that indirectly augment dopamine activity through serotonin antagonism (high 5-HT<sub>2</sub>/D<sub>2</sub> ratio) and partial D<sub>2</sub> agonism are being tested. While these diminish EPS liability, they do not eliminate EPS altogether. Both risperidone and ziprasidone exhibit strong serotonin antagonist activity; however, this is insufficient to prevent EPS in the case of risperidone. For ziprasidone, this assertion is valid to a lesser extent. Patients who switched from conventional antipsychotics or risperidone to ziprasidone experienced fewer EPS after six weeks of ziprasidone treatment. That said, the EPS risk of risperidone below the doses of 6 mg per day is low. Across a therapeutic dose range of 0.5–16 mg per day, there is a significant linear correlation between the dose of risperidone and the incidence of EPS, which is still associated with fewer adverse effects than high-potency FGAs. Both quetiapine and clozapine have significant 5-HT<sub>2A</sub> antagonism, but they also possess unique properties that reduce D<sub>2</sub> antagonism. Aripiprazole has a very low EPS liability despite having a striatal D<sub>2</sub> occupancy rate between 80% and 90%. This phenomenon can be attributed to the partial agonist properties of aripiprazole. Specifically, the agonist activity is 30%, which is sufficient to maintain normal dopaminergic motor activity.<sup>17,18</sup>

According to a meta-analysis on EPS associated with antipsychotics, quetiapine is associated with the least incidence of dystonia (1.4%), paliperidone is associated with the least incidence of akathisia (3.3%), while clozapine is associated with the least incidence of parkinsonism (3.7%) and tremor (0.2%). Haloperidol shows very high rates of these side effects, ranging from 16% to 24%.<sup>19</sup> Clozapine is typically reserved for treatment-resistant patients due to the serious side effect of agranulocytosis. However, some studies suggest that clozapine may lead to symptom resolution for tardive dyskinesia, especially in cases of tardive dystonia.<sup>12,16</sup>

19

Children with disabilities face a higher risk of obesity compared to the general population of children. Patients with diplegic or quadriplegic CP may be wheelchair-bound, and the adverse effects of antipsychotics, such as metabolic syndrome and weight gain, should be considered more seriously in this population. Reduced mobility, restricted social participation, and an increase in depressive symptoms significantly contribute to weight gain within this group.<sup>2, 20, 21</sup> In patients with limited mobility, the incidence of pressure ulcers increases. Although being obese may provide some protection against pressure ulcers, extremely obese individuals (BMI>40) have higher rates of pressure ulcers compared to patients with a normal weight. Overall, both being underweight and extremely obese are risk factors for developing pressure ulcers.<sup>22</sup> Studies indicate that individuals with cerebral palsy (CP) who carry excess weight around the belly experience gait problems, resulting in slower walking speeds, shorter step lengths, and reduced ranges of joint motion. They also exhibit decreased moments and powers during movement.<sup>23</sup> Furthermore, 36% of CP patients are affected by hip disorders. Spasticity can contribute to hip pain and dislocation, and as individuals gain weight, the compressive and shear forces on the hip during walking increase. This additional load on the hip joint raises the risk of developing hip pain and related pathologies.<sup>3, 24</sup> Moreover, increased weight can heighten the need for caregiver assistance in daily activities, making their responsibilities more challenging.<sup>20</sup>

5

A meta-analysis examining weight gain as an adverse effect of antipsychotics indicates that olanzapine is associated with the most clinically relevant weight gain within six weeks of treatment, affecting 24.1% of patients compared to 1.4% on placebo. Following olanzapine, risperidone results in weight gain for 16.8% of patients, compared to 2.9% on placebo, while aripiprazole shows a 16.8% weight gain versus 7% on placebo. Quetiapine is associated with weight gain in 12.5% of patients compared to 6% on placebo.<sup>25</sup>

5

In another comprehensive study, clozapine and olanzapine were identified as having the highest risk of weight gain, with olanzapine at the top of the list. Mid-risk antipsychotics include asenapine, risperidone, paliperidone, and quetiapine. The antipsychotics associated with the lowest risk of weight gain are aripiprazole, lurasidone, and ziprasidone. Haloperidol is also noted to cause less weight gain than second-generation antipsychotics (SGAs).<sup>26, 27</sup>

## Conclusion

We aimed to demonstrate how these adverse effects of antipsychotic medications impact the lives of cerebral palsy patients, and which medications carry a higher risk. Also, we sought to highlight that the treatment of bipolar disorder in patients with cerebral palsy should be customized by considering their specific clinical characteristics. These characteristics can include the subtype of CP (spastic, ataxic, or dyskinetic), which limb is affected, wheelchair dependency, the presence of pre-existing hip disorders, and their Body Mass Index (BMI). By considering the patient profile, physicians can better prioritize whether to be more cautious about extrapyramidal or metabolic adverse effects of antipsychotics. This approach will help choose the most appropriate medication and optimize outcomes for this population. To our knowledge, this topic has not been addressed previously in the literature, and further research is essential to guide clinical decision-making in this overlooked group.

## References

- 1 Upadhyay, J., Tiwari, N., & Ansari, M. N. (2020). Cerebral palsy: Aetiology, pathophysiology, and therapeutic interventions. *Clinical and Experimental Pharmacology & Physiology*, 47(12), 1891–1901. <https://doi.org/10.1111/1440-1681.13379>
- 2 Krigger, K. W. (2006). Cerebral palsy: An overview. *American Family Physician*, 73(1), 91–100.
- 3 Vitrikas, K., Dalton, H., & Breish, D. (2020). Cerebral palsy: An overview. *American Family Physician*, 101(4), 213–220.
- 4 McMorris, C. A., Lake, J., Dobranowski, K., McGarry, C., Lin, E., Wilton, D., Lunsby, Y., & Balogh, R. (2021). Psychiatric disorders in adults with cerebral palsy. *Research in Developmental Disabilities*, 111, 103859. <https://doi.org/10.1016/j.ridd.2021.103859>
- 5 Bjorgaas, H. M., Hysing, M., & Elgen, I. (2012). Psychiatric disorders among children with cerebral palsy at school starting age. *Research in Developmental Disabilities*, 33(4), 1287–1293.
- 6 Downs, J., Blackmore, A. M., Epstein, A., Skoss, R., Langdon, K., Jacoby, P., Whitehouse, A. J. O., Leonard, H., Rowe, P. W., & Glasson, E. J.; Cerebral Palsy Mental Health Group. (2018). The prevalence of mental health disorders and symptoms in children and adolescents with cerebral palsy: A systematic review and meta-analysis. *Developmental Medicine & Child Neurology*, 60(1), 30–38.
- 7 American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed., pp. 123–126). American Psychiatric Publishing.
- 8 Goes, F. S. (2023). Diagnosis and management of bipolar disorders. *BMJ*, 381, e073591.
- 9 Schindzielorz, A. (2022). Increased sensitivity to serotonin syndrome in cerebral palsy. *Case Reports in Psychiatry*, 2022(9), 1–3.
- 10 Mortimer, D., Gelfius, C. D., & Potts, M. A. (2013). Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: A case report. *PM&R*, 5(12), 1077–1080.
- 11 Viejo, L. F., Morales, V., Puñal, P., Pérez, J. L., & Sancho, R. A. (2003). Risk factors in neuroleptic malignant syndrome: A case-control study. *Acta Psychiatrica Scandinavica*, 107(1), 45–49.
- 12 Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. *Drug Safety*, 28(3), 191–208.
- 13 Chan, C.-H., Gau, S. S.-F., Chan, H.-Y., Tsai, Y.-J., Chiu, C.-C., Wang, S.-M., & Huang, M.-L. (2013). Risk factors for falling in psychiatric inpatients: A prospective, matched case-control study. *Journal of Psychiatric Research*, 47(8), 1088–1094.
- 14 Van Harten, P. N., & Kahn, R. S. (1999). Tardive dystonia. *Schizophrenia Bulletin*, 25(4), 741–748.



- 15 Kreisler, A., Verpraet, A.-C., Veit, S., Pennel-Ployart, O., Béhal, H., Duhamel, A., & Destée, A. (2016). Clinical characteristics of voice, speech, and swallowing disorders in oromandibular dystonia. *Journal of Speech, Language, and Hearing Research*, 59(5), 940–949.
- 16 Adrianzén, C., Arango-Dávila, C., Martínez Araujo, D., Ruiz, I., Walton, R. J., Dossenbach, M., & Karagianis, J. (2010). Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: Post hoc analysis from a 3-year observational study. *Human Psychopharmacology: Clinical and Experimental*, 25(6), 439–447.
- 17 Weiden, P. J. (2007). EPS profiles: The atypical antipsychotics are not all the same. *Journal of Psychiatric Practice*, 13(1), 13–24.
- 18 Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006). Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. *Neuropsychopharmacology*, 31(9), 1854–1863.
- 19 Martino, D., Karnik, V., Osland, S., Barnes, T. R. E., & Pringsheim, T. M. (2018). Movement disorders associated with antipsychotic medication in people with schizophrenia: An overview of Cochrane reviews and meta-analysis. *The Canadian Journal of Psychiatry*, 63(11), 730–739.
- 20 Dogruoz Karatekin, B., Kacar, G., & Icgasioglu, A. (2023). Obesity in ambulatory children with cerebral palsy in Turkey: A cross-sectional study. *Journal of Pediatric Rehabilitation Medicine*, 16(1), 195–202.
- 21 Kiernan, D., Nikolopoulou, C., & Brady, K. (2021). Prevalence of overweight and obesity in Irish ambulant children with cerebral palsy. *Irish Journal of Medical Science*, 190(1), 225–231.
- 22 Hyun, S., Li, X., Vermillion, B., Newton, C., Fall, M., Kaewprag, P., Moffatt-Bruce, S., & Lenz, E. R. (2014). Body mass index and pressure ulcers: Improved predictability of pressure ulcers in intensive care patients. *American Journal of Critical Care*, 23(6), 494–501.
- 23 Meyns, P., Van Gestel, L., Bar-On, L., Goudriaan, M., Wambacq, H., Aertbeliën, E., Bruyninckx, H., Molenaers, G., De Cock, P., Ortibus, E., & Desloovere, K. (2016). Children with spastic cerebral palsy experience difficulties adjusting their gait pattern to weight added to the waist, while typically developing children do not. *Frontiers in Human Neuroscience*, 10, 657.
- 24 Lerner, Z. F., & Browning, R. C. (2016). Compressive and shear hip joint contact forces are affected by pediatric obesity during walking. *Journal of Biomechanics*, 49(9), 1547–1553. <https://doi.org/10.1016/j.jbiomech.2016.03.033>
- 25 Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weight-gain caused by antipsychotics: A systematic review and meta-analysis. *Expert Opinion on Drug Safety*, 19(3), 295–314.
- 26 Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2015). Weight gain and antipsychotics: A drug safety review. *Expert Opinion on Drug Safety*, 14(1), 73–96.
- 27 Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. *The Lancet*, 373(9657), 31–41.

# Treatment of Bipolar Disorder in Cerebral Palsy: Challenges in Antipsychotic Use

## ORIGINALITY REPORT

20%

SIMILARITY INDEX

13%

INTERNET SOURCES

13%

PUBLICATIONS

4%

STUDENT PAPERS

## PRIMARY SOURCES

1

[journals.lww.com](http://journals.lww.com)

Internet Source

5%

2

[listens.online](http://listens.online)

Internet Source

2%

3

Diane Mortimer, Carl D. Gelfius, Michelle A. Potts. "Deleterious Cognitive and Motoric Effects of Haloperidol in an Adolescent With Cerebral Palsy: A Case Report", PM&R, 2013

Publication

1%

4

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

Internet Source

1%

5

D. M. Taylor, R. McAskill. "Atypical antipsychotics and weightgain — a systematic review", Acta Psychiatrica Scandinavica, 2001

Publication

1%

6

Submitted to University of Wisconsin, Madison

Student Paper

1%

7

[vdoc.pub](http://vdoc.pub)

Internet Source

1%

8

Submitted to University of Witwatersrand

Student Paper

1%

9

"Comorbid Conditions in Individuals with Intellectual Disabilities", Springer Science and Business Media LLC, 2015

Publication

1%

10	<a href="http://www.scielo.org.za">www.scielo.org.za</a> Internet Source	1 %
11	"Psychiatry of Intellectual Disability", Wiley, 2012 Publication	1 %
12	Submitted to Queen Mary and Westfield College Student Paper	1 %
13	<a href="http://williamlittlefoundation.org">williamlittlefoundation.org</a> Internet Source	1 %
14	"Drug Induced Movement Disorders", Wiley, 2005 Publication	<1 %
15	<a href="http://journal.frontiersin.org">journal.frontiersin.org</a> Internet Source	<1 %
16	<a href="http://archive-ouverte.unige.ch">archive-ouverte.unige.ch</a> Internet Source	<1 %
17	<a href="http://iris.unipv.it">iris.unipv.it</a> Internet Source	<1 %
18	<a href="http://www.scribd.com">www.scribd.com</a> Internet Source	<1 %
19	Justin A. Haegele, Samuel R. Hodge, Deborah R. Shapiro. "Routledge Handbook of Adapted Physical Education", Routledge, 2020 Publication	<1 %
20	<a href="http://wiredspace.wits.ac.za">wiredspace.wits.ac.za</a> Internet Source	<1 %
21	Zachary F. Lerner, Raymond C. Browning. "Compressive and shear hip joint contact forces are affected by pediatric obesity during walking", Journal of Biomechanics, 2016 Publication	<1 %

22

curis.ku.dk

Internet Source

&lt;1 %

23

"XXIst CINP Congress: Brussels, Belgium, 9-13 July 2000", The International Journal of Neuropsychopharmacology, 2007

Publication

&lt;1 %

24

Anna Linder, Johan Jarl, Kristina Tedroff. "A life course perspective on mental disorders and psychopharmacologic drug use among persons living with cerebral palsy", European Journal of Paediatric Neurology, 2024

Publication

&lt;1 %

25

PETER J. WEIDEN. "EPS Profiles: The Atypical Antipsychotics", Journal of Psychiatric Practice, 2007

Publication

&lt;1 %

Exclude quotes

On

Exclude matches

Off

Exclude bibliography

On